For the year ending 2025-12-31, VIR had -$77,625K decrease in cash & cash equivalents over the period. -$396,613K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -437,987 |
| Depreciation and amortization | 11,680 |
| Amortization of premiums (accretion of discounts) on investments, net | -9,474 |
| Noncash lease expense | 4,980 |
| Change in fair value of equity investments | -1,729 |
| Change in estimated fair value of contingent consideration | 11,490 |
| Payment of contingent consideration in excess of acquisition date fair value | -17,140 |
| Stock-based compensation | 49,072 |
| In-process research and development impairment | 0 |
| Non-cash restructuring, long-lived assets impairment and related charges | 654 |
| Other non-cash items, net | 172 |
| Prepaid expenses and other current assets | -2,075 |
| Other assets | 12,642 |
| Accounts payable | 4,997 |
| Accrued liabilities and other long-term liabilities | -9,509 |
| Operating lease liabilities | -7,368 |
| Net cash used in operating activities | -391,781 |
| Proceeds from sale of equipment | 253 |
| Purchases of long-lived assets | 4,832 |
| Purchases of investments | 886,334 |
| Maturities and sales of investments | 1,201,284 |
| Net cash provided by investing activities | 310,371 |
| Proceeds from exercise of stock options | 1,349 |
| Proceeds from issuance of common stock under espp | 2,797 |
| Other financing activities | -361 |
| Net cash provided by financing activities | 3,785 |
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | -77,625 |
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 318,695 |
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | 241,070 |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)